<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<pubmed-document>
<record>
<header>
<identifier>24269470</identifier>
<setSpec>1989-7286</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:author>Junceda-Moreno, J</dc:author>
<dc:author>Rodríguez-García, M</dc:author>
<dc:author>Fernández-Alonso, R</dc:author>
<dc:author>Pérez-Carro, G</dc:author>
<dc:author>González-Diéguez, M L</dc:author>
<dc:description xml:lang="en">Clinical case A patient with chronic, painless, bilateral loss of vision, after significant intake of interferon (IFNα) and ribavirina due to liver transplant. Ocular fundus is normal. A suspected retrobulbar optic neuropathy is confirmed by a prolongation of the latency of the patient's visual evoked potential. There being no prior record of risk factors and with the patient's systemic analysis giving normal results, the clinical improvement and the electro-physiological tests conducted after the drug was withdrawn point to interferon as negatively affecting the bilateral optic nerve. Discussion Interferon-α is used in the treatment of viral and neoplastic illnesses. Currently the drug is formulated as Interferon alfa pegilado (IFNα-p) in order to reduce toxicity and increase tolerance. The most common secondary effects are flu symptoms, asthenia and weigh loss. Affected ocular tissue is rare and optic neuropathy is also an infrequent complication: retinopathy at the beginning of treatment is, however, more frequent. The most widely accepted hypothesis as to the cause of toxicity is the presence of circulating immune complexes. It is, therefore, essential for ophthalmologists to be aware of the toxicity of this drug in order to be able to withdraw it in good time, thus preventing potentially irreversible sight loss.</dc:description>
<dc:type>Case Reports</dc:type>
<dc:language>es</dc:language>
<dc:subject>Chronic hepatitis due to VHC</dc:subject>
<dc:subject>Toxic optical neuropathy</dc:subject>
<dc:subject>Latencia prolongada</dc:subject>
<dc:subject>Hepatitis crónica por VHC</dc:subject>
<dc:subject>Evoked visual potentials</dc:subject>
<dc:subject>Potenciales evocados visuales</dc:subject>
<dc:subject>Interferón alfa pegilado</dc:subject>
<dc:subject>Neuropatía óptica tóxica</dc:subject>
<dc:subject>Prolonged latency</dc:subject>
<dc:subject>Pegylated Interferon alpha</dc:subject>
<dc:date>2014 Apr </dc:date>
<dc:title xml:lang="es">Toxicidad por interferón alfa y neuropatía óptica bilateral reversible: una retirada a tiempo.</dc:title>
<dc:title xml:lang="en">[Interferon-alpha toxicity and reversible bilateral optical neuropathy: a timely withdrawal of the drug].</dc:title>
<dc:publisher>Archivos de la Sociedad Espanola de Oftalmologia</dc:publisher>
</metadata>
</record>
</pubmed-document>
